Redeye initiates coverage of Promore Pharma

We are initiating coverage on Promore Pharma, a Swedish biotech company with a focus on peptide-based drugs in wound healing. We see a lopsided risk/reward on an 18-24 month investment horizon.

Read more and download the Research Report: https://goo.gl/bnshv1

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/